| AbbVie AG - Skyrizi 600 mg/10 ml, Konzentrat zur Herstellung einer Infusionslösung |
| 68947 | | 01 | | Skyrizi 600 mg/10 ml | | Konzentrat zur Herstellung einer Infusionslösung | | L04AC18 | | Risankizumab | | 14.09.2023 | | |
|
| Composition |
| risankizumabum 600 mg, natrii acetas trihydricus corresp. natrium 2.09 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 10 ml. |
| Packungsbestandteile |
| Concentré pour perfusion | | | | | | | | Principe actif | Concentr. |
|---|
| Risankizumabum | 600mg / 10ml |
| | BAG: Principe actif | Concentr. |
|---|
| Risankizumabum | 600 mg |
| | | | Agents auxilliaires |
|---|
| Acidum Aceticum Glaciale | | Sodium Acetate Trihydrate | | Polysorbatum 20 | | Trehalosum Dihydricum |
| |
|
|
